Cholesterol Newswire

Cholesterol Newswire

Comprehensive Real-Time News Feed for Cholesterol.

Results 1 - 20 of 926 in Cholesterol

  1. MomentumWE have OvercomeRead the original story

    2 hrs ago | American Reporter

    We made food history last week when Indiana declared the Wick's sugar cream as its very own State Pie. I celebrated the event by having my wife tell me I couldn't eat any because of my cholesterol.

    Comment?

  2. Top Drug Stock Pfizer In Buy Area After Earnings BeatRead the original story w/Photo

    Friday Jul 31 | Investor's Business Daily

    The maker of blockbuster drugs such as Viagra and cholesterol fighter Lipitor broke out past a 35.63 buy point of a flat base in heavy volume on Wednesday. It remains within the 5% limit that defines a buy range.

    Comment?

  3. MomentumWE have OvercomeRead the original story

    Friday Jul 31 | American Reporter

    We made food history last week when Indiana declared the Wick's sugar cream as its very own State Pie. I celebrated the event by having my wife tell me I couldn't eat any because of my cholesterol.

    Comment?

  4. Amgen hikes 2015 forecast after 2Q increase in profit, salesRead the original story w/Photo

    Thursday Jul 30 | NewsOK.com

    ... Kyprolis, approved in the U.S., awaits European approval, while Repatha, an expensive biologic drug for lowering cholesterol in patients not helped enough by statin pills such as Lipitor, was approved in Europe this month and could win U.S. Approval ...

    Comment?

  5. Preventable onset of myocardial infarction through coadministration of two drugsRead the original story w/Photo

    Thursday Jul 30 | PhysOrg Weblog

    Ischemic heart disease is the leading cause of death in the world and second in Japan behind cancer. It causes blood vessels to become clogged or narrowed through the buildup of cholesterol plaque along the inside of artery walls.

    Comment?

  6. New Drug Lowers Heart-Damaging TriglyceridesRead the original story w/Photo

    Thursday Jul 30 | News Max

    ... much higher levels, which is associated with insulin resistance, metabolic syndrome, diabetes, inherited high cholesterol and certain other disorders, the researchers explained. Metabolic syndrome is a combination of high blood pressure, high ...

    Comment?

  7. Express Scripts says costly new cholesterol drugs could 'wreak havoc'Read the original story

    Thursday Jul 30 | Fox News

    Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. U.S. regulators last Friday approved the first of the new medicines, Praluent, from Regeneron Pharmaceuticals Inc and Sanofi SA.

    Comment?

  8. Drug firm AstraZeneca reports slide in earningsRead the original story w/Photo

    Thursday Jul 30 | The New Zealand Herald

    " Anglo-Swedish drug firm AstraZeneca says second-quarter net income fell 12 percent to $697 million as competition from generic drug companies reduced sales. Revenue declined 6.7 percent to $6.31 billion as stomach-acid treatment Nexium lost patent exclusivity in the U.S. and cholesterol treatment Crestor faced competition from generic drugs.

    Comment?

  9. Anglo-Swedish drug firm AstraZeneca reports slide in second quarter profitsRead the original story

    Thursday Jul 30 | Canadian Business Magazine

    Anglo-Swedish drug firm AstraZeneca says second-quarter net income fell 12 per cent to $697 million as competition from generic drug companies reduced sales. Revenue declined 6.7 per cent to $6.31 billion as stomach-acid treatment Nexium lost patent exclusivity in the U.S. and cholesterol treatment Crestor faced competition from generic drugs.

    Comment?

  10. New Drug Lowers Levels of Triglyceride Blood FatsRead the original story w/Photo

    Wednesday Jul 29 | MedlinePlus

    ... much higher levels, which is associated with insulin resistance, metabolic syndrome, diabetes, inherited high cholesterol and certain other disorders, the researchers explained. Metabolic syndrome is a combination of high blood pressure, high ...

    Comment?

  11. New cholesterol drug - $14,600 a yearRead the original story w/Photo

    Wednesday Jul 29 | WTSP-TV Saint Petersburg

    Up to 10 million Americans will soon have a new option for lowering their cholesterol - at a price of $14,600 a year. FDA approves new cholesterol drug - at $14,600 a year Up to 10 million Americans will soon have a new option for lowering their cholesterol - at a price of $14,600 a year.

    Comment?

  12. New Drug Lowers Levels of Triglyceride Blood Fats: StudyRead the original story w/Photo

    Wednesday Jul 29 | HON

    ... much higher levels, which is associated with insulin resistance, metabolic syndrome, diabetes, inherited high cholesterol and certain other disorders, the researchers explained. Metabolic syndrome is a combination of high blood pressure, high ...

    Comment?

  13. UPDATE 3-Express Scripts says costly new cholesterol drugs could 'wreak havoc'Read the original story

    Wednesday Jul 29 | Reuters

    Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. U.S. regulators last Friday approved the first of the new medicines, Praluent, from Regeneron Pharmaceuticals Inc and Sanofi SA.

    Comment?

  14. What to Watch in the Day Ahead - Thursday, July 30Read the original story

    Wednesday Jul 29 | Reuters

    ... will be looking for details on the company's plans for the European launch of its recently approved injectable cholesterol treatment, as well as its expectations for the drug's U.S. approval and launch in the coming weeks. Cigna Corp, which agreed ...

    Comment?

  15. Atorvastatin/Ezetimibe beats atorvastatin after PCIRead the original story w/Photo

    Wednesday Jul 29 | PhysOrg Weblog

    ... monotherapy, the combination of atorvastatin/ezetimibe resulted in lower levels of low-density lipoprotein cholesterol (63.2 A 16.3 mg/dL versus 73.3 A 20.3 mg/dL; P < 0.001). The mean between-group difference in the absolute change in percent ...

    Comment?

  16. Leena Spices Special: Exotic And All-natural Lentil Masala Spice Blend From World Over At AmazonRead the original story

    Wednesday Jul 29 | Emailwire.com

    ... and lean protein. As one of the staple food in the world, lentils are known for its health benefits such as low cholesterol and fat content, can regulate bowel movement and promote digestive system health. Eating plenty of nutrient dense foods like ...

    Comment?

  17. Pfizer Pulls Plug on OTC Lipitor After Trial FailureRead the original story

    Tuesday Jul 28 | BioSpace

    Pfizer Inc. won't bring an over-the-counter version of its cholesterol pill Lipitor to the U.S. market, after a trial found that patients couldn't take the drug correctly without a doctor's help. Pfizer's decision to kill the over-the-counter program ends a years-long effort designed to preserve sales of what was once the New York-based company's -- and the world's -- top-selling drug.

    Comment?

  18. Pfizer Quits Over-the-Counter Lipitor Program After Trial FailsRead the original story

    Tuesday Jul 28 | The Washington Post

    Pfizer Inc. won't bring an over-the-counter version of its cholesterol pill Lipitor to the U.S. market, after a trial found that patients couldn't take the drug correctly without a doctor's help. Pfizer's decision to kill the over-the-counter program ends a years-long effort designed to preserve sales of what was once the New York-based company's -- and the world's -- top-selling drug.

    Comment?

  19. Regeneron and Sanofi's cholesterol treatment, Praluent gets FDA approvalRead the original story

    Tuesday Jul 28 | PR Log

    Injection to treat high LDL Cholesterol in adult patients. Praluent was co-developed by Sanofi and Regeneron and is the first approved PCSK9 Inhibitor in a new class of drugs known as PCSK9 inhibitors.

    Comment?

  20. French pharmaceutical giant invests at least $1.7 billion in Regeneron cancer drugRead the original story w/Photo

    Tuesday Jul 28 | Business Journal

    Days after a cholesterol-lowering drug that Regeneron Pharmaceuticals Inc. developed with French company Sanofi won FDA approval , the two companies announced a new partnership to develop a cancer treatment. Sanofi agreed to pay at least $1.7 billion to Regeneron , a major employer in the Albany region.

    Comment?